The chairman of China Pharmaceuticals, a well-known pharmaceutical company, resigned

Pharma.com February 4 - China Pharmaceuticals Chairman resigns Feb. 3, one of the three major state-owned enterprises with the pharmaceutical industry as its main business, China Pharmaceuticals announced that Chairman Gao Yuwen, due to work adjustment reasons, applied to resign as chairman of the company (legal representative), director and the board of directors of the relevant positions of the special committee.
Gao Yuwen's resignation application shall take effect from the date of service to the board of directors, after which Gao Yuwen will no longer hold any position in China Medicine, and China Medicine will complete the election of the new director and chairman in accordance with the legal procedures as soon as possible.
According to SaiBaiLan inquiry, china's pharmaceutical official website data show that from July 2008 to May 2013, Gao Yuwen began to serve as general manager of the pharmaceutical business unit of general technology group (medical control company), deputy secretary of the Party Committee; From June 2013 to March 2018, he served as Deputy Secretary and General Manager of the Chinese Pharmaceutical Party Committee, director of China Pharmaceuticals from August 2013 to date, and as Party Secretary and Chairman of the Chinese Pharmaceutical Party Committee from March 2018 to the present.
Prior to Gao Yuwen, on June 2 last year, Hou Wenling, director and general manager of China Pharmaceuticals, also applied to resign from his position as a director, general manager and special committee member of the board of directors for work adjustment reasons, and will no longer hold any positions in China Medicine.
the new general manager of China Pharmaceuticals will be Wang Hongxin until the 8th Board of Directors of China Pharmaceuticals expires.
, 53-year-old master's degree, assistant international business division, has served as general manager of China Pharmaceutical Integrated Trade Department, assistant general manager, director, deputy general manager, currently general manager.
One of the three major central enterprises, Known as China Pharmaceutical And Health Industry Co., Ltd., is a state-controlled listed company listed on the Shanghai Stock Exchange, the controlling shareholder is China General Technology (Group) Holdings Co., Ltd., with a registered capital of 1.068 billion yuan, and is one of the three major central enterprises with the pharmaceutical industry as its main business.
China Pharma's predecessor was the China Medical and Health Products Import and Export Corporation under the former Ministry of Foreign Trade and Economic Cooperation in 1984, responsible for managing the national pharmaceutical and health care products import and export industry, in 1999 joined China General Technology Group, after the group's internal pharmaceutical assets reorganization, become the Group's only pharmaceutical assets integration platform.
, China Pharma through the acquisition of Meikang Baitai Pharmaceutical Technology Co., Ltd., Meikang Kyusju Pharmaceutical Co., Ltd., etc., mainly to establish a nationwide coverage of 32 provinces and autonomous regions of the marketing network.
, China's pharmaceutical business scope involves international trade, pharmaceutical industry, pharmaceutical business, natural medicine and other fields.
international trade sector: involving natural medicines, pharmaceutical chemicals, medical devices, health products, marketing network covering the major emerging and developed countries of the pharmaceutical market.
Pharmaceutical industry sector: the field of production involves chemical raw materials, biological raw materials, chemical drugs, traditional Chinese medicine, natural medicine, pharmaceutical health care products and finished preparations production, products include antibiotic fermentation raw materials, chemical synthetic raw materials, tablets, needles, capsules, etc. ;
Pharma commercial sector: in North China, Northeast, South China, Central China, East China, Northwest china and other regions to Beijing, Guangdong, Henan, Hebei, Chongqing, Jiangxi and Xinjiang as the core of the pharmaceutical commercial pure sales network system, in Central China, East China and other regions set up a retail chain of pharmacies.
Natural Medicine Plate: Business includes the cultivation and cooperative cultivation of large varieties of medicinal herbs, initial processing of origin, domestic beverage tablet production, export medicinal processing, domestic sales, foreign imports of medicinal herbs, pharmaceutical exports, sales of health food raw materials.
Policy changes and corporate responses In the face of the complex and changing market environment, China Pharmaceuticals continues to promote business restructuring and business transformation, increase end-market development and expansion of pure sales business, accelerate regional network layout, expand international market business, optimize business resource allocation, strengthen business model transformation and innovation, and achieve sustained growth in operating income.
However, the pharmaceutical industry sector was affected by policy factors such as "volume procurement" and "limiting resistance" and the continuous adjustment of the industrial marketing system, some products were not selling well, the scale of sales of high gross margin varieties was reduced, and individual enterprises stopped selling, resulting in a decline in overall profitability.
China Pharma's 2019 financial results showed that last year's full-year operating income was RMB35,285 million, up 13.80 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB981 million, down 36.46 percent year-on-year.
In the past few years, the domestic pharmaceutical industry policy has been continuously reformed: although the growth rate of the main business income of the pharmaceutical industry has gradually picked up since 2015, but in recent years by the health insurance control fees, volume procurement expansion, consistent evaluation and a series of policy factors affecting the overall growth rate fell, 2019 Annual revenue growth slowed to 7.4% from 12.6% in 2018, while total profit growth slowed to 5.9% from 9.5% in 2018; The growth rate of total sales fell back to 7.5% in 8 years, and in 2019, with the market's digestion of the "two-vote system" policy, the growth rate of total sales bottomed out and rebounded, up 9.8% YoY, but under the influence of the comprehensive implementation of the medical reform policy, the growth rate of total industry profits slowed year by year,2 The growth rate in 2019 was 8.5%, the policy effect of persisting in opening up to the outside world and the steady growth of foreign trade continued to show, the growth rate of foreign trade exports of pharmaceutical products rebounded slightly, the bottom of imports rebounded, and in 2019, the export volume of pharmaceutical products increased by 14.6% YoY. Imports of pharmaceutical products increased by 42.5% year-on-year.
With the further promotion of national medical reform, the impact of various policies and overlay effects will be further revealed, the pharmaceutical industry presents more active enterprise innovation, the industry reshuffle continues to intensify the situation, the pharmaceutical industry's advantages and disadvantages differentiation accelerates, the industry concentration will continue to improve, the new market pattern is forming, in the process, enterprises are also giving their own response.